Including events rescheduled due to COVID-19, the calendar provides a list of upcoming conferences, workshops and educational events, with dates, locations and web links for more information and registration.
June 2020 Inhalation
that dates may change further, so
stay in touch with the organizers.
July
Inhalation & Respiratory Drug
Delivery UK (Virtual). July 8-9,
2020. https://www.oxfordglobal.
co.uk
September
Pulmonary Drug Delivery. Sep-
tember 2-4, 2020 in Dublin,
Ireland. www.pulmonar ydrug
delivery.org
Metered Dose Inhaler Technol-
ogy. September 16-17, 2020 in
London, UK. https://manage
ment-forum.co.uk
Aerosol School. Canceled for
2020. Please check for updates.
https://www.isam.org
Inhalation & Respiratory Drug
Delivery Congress US (Virtual).
September 29-30, 2020. https://
www.oxfordglobal.co.uk
October
Drug Deliver y Partnerships.
October 12-14, 2020 in Orlando,
FL, US. http://informaconnect.
com/ddp
Association of Inhalation Toxi-
cologists. To be replaced for 2020
by online lectures. https://www.
aitoxicology.org
MVIS Symposium & Workshop.
October 19-22, 2020 in Lund, Swe-
den. http://symposium.mvic.se
AAPS PharmSci360. October
25-28, 2020 in New Orleans, LA,
US. https://www.aaps.org
November
Inhaled Drug Delivery. Novem-
ber 3-4, 2020 in London, UK.
https://management-forum.co.uk
RDD Asia 2020. November 4-6,
2020 in Goa, India. https://www.
rddonline.com
December
The Christmas Lectures (Vir-
tual). (Replaces Drug Delivery to
the Lungs 2020.) December 9-11,
2020. https://ddl- conference.com
GmbH announced an exclusive
partnership to develop mRNA-
e n c o d e d , n e u t r a l i z i n g a n t i -
SARS- CoV-2 antibodies to be
administered by inhalation for
treatment of COVID-19. Neurim-
mune is identifying human anti-
SARS-CoV-2 antibodies from
the immune cells of recovered
COVID-19 patients using its
RT M
™ t e c h n o l o g y p l a t f o r m .
Potent neutralizing antibodies
will be translated into therapeu-
tic products for inhalation using
Ethris' proprietary pulmonary
SNIM
®
RNA technology. The
companies noted that production
of specific, neutralizing antibodies
directly in patients' lungs provides
the opportunity to significantly
impact the viral lung disease that
is the primary driver of morbid-
ity and mortality. The planned
treatment could be effective in all
COVID-19 patients. The com-
panies plan to begin manufactur-
ing the drug product for clinical
trials in the summer of 2020. e
first candidate is expected to begin
clinical testing in the fourth quar-
ter of 2020, pending regulatory
approval. Ethris focuses on deliv-
ery of mRNA directly to the respi-
ratory system by nebulization and
the company collaborates with
AstraZeneca in asthma, chronic
obstructive pulmonary disease and
idiopathic pulmonary fibrosis.
FDA grants Bellerophon
emergency expanded access
for COVID-19 treatment
WA R R E N , N EW J E R S EY —
According to Globe Newswire,
Bellerophon Therapeutics, Inc.
announced that the United States
Food and Drug Administration
(FDA) has granted emergency
expanded access allowing its pro-
prietary inhaled nitric oxide (iNO)
delivery system, INOpulse
®
, to
immediately be used for the treat-
ment of COVID-19. A company
news release explained that "NO is
a naturally produced molecule that
is critical to the immune response
against pathogens and infections.
In vitro studies have shown that
it inhibits replication of severe
acute respiratory syndrome-related
coronavirus (SARS-CoV) and
improves survival for cells infected
with SARS-CoV. In a clinical study
of patients infected with SARS-
CoV, iNO demonstrated improve-
ments in arterial oxygenation, a
reduction in the need for venti-
lation support and an improve-
ment in lung infiltrates observed
on chest radiography. Based on
the genetic similarities between
the two coronaviruses, the data in
SARS-CoV support the poten-
tial for iNO to provide meaning-
ful benefit for patients infected
with COVID-19." Further, Fabian
Tenenbaum, Chief Executive Offi-
cer of Bellerophon, noted that
"INOpulse is designed to treat
patients in the outpatient setting,
which may be critical in helping
combat the further spread of the
virus and significantly alleviate the
mounting impact on hospitals and
intensive care units."
Calendar
As of May 19, the following events
have been revised or rescheduled
due to COVID-19 or are scheduled
as initially planned. Please be aware
advertiser index
A
Astech 7
C
Catalent Pharma Solutions Cover 2
Cliantha Research 17
Copley Scientific 3
E
Experic 9
M
Merxin Ltd. 8
MSP 1
P
Presspart Manufacturing Ltd 11
Proveris 15
Q
Qualicaps 25
R
RDD Cover 3
Recipharm 5
